Bone Resorption Assay Kit 使用論文

RAW264、RAW264.7
1) Kim JL, Osteoblastogenesis and osteoprotection enhanced by flavonolignan silibininin osteoblasts and osteoclasts.

J Cell Biochem. 2012, 113(1):247-59. PMID:21898547
2) Tanaka H, Nicotine affects bone resorption and suppresses the expression ofcathepsin K, MMP-9 and vacuolar-type H(+)-ATPase d2 and actin organization inosteoclasts. PLoS One. 2013, 8(3):e59402. PMID: 23555029
3) Sapkota M, Bromo-honaucin A inhibits osteoclastogenic differentiation in RAW 264.7
cells via Akt and ERK signaling pathways. Eur J Pharmacol, 2015, 769:100-9. PMID:26550952
4) Choe CH, Transmembrane protein 173 inhibits RANKL-induced osteoclastdifferentiation. FEBS Lett. 2015, 589(7):836-41. PMID: 25728277
5) Li L, Herbacetin inhibits RANKL-mediated osteoclastogenesis in vitro and prevents
inflammatory bone loss in vivo. Eur J Pharmacol. 2016, 777:17-25. PMID: 26923730
6) Shiota J, Iguratimod, a Disease-Modifying Anti-Rheumatic Drug, Inhibits
Osteoclastogenesis and Bone Resorption through Suppression of the Nuclear Factorof Activated T Cells Signaling Pathway. Open Journal of Rheumatology andAutoimmune Diseases, 2016, 6, 106-119
7) Qiu ZC, Discovery of a New Class of Cathepsin K Inhibitors in Rhizoma Drynariaeas Potential Candidates for the Treatment of Osteoporosis. Int J Mol Sci. 2016,17(12):2116. PMID: 27999266
8) Ishikawa S., Inductive Effect of Palmatine on Apoptosis in RAW 264.7 Cells. EvidBased Complement Alternat Med, 2016, 2016:7262054. PMID: 27340419
9) Lee SH, Anti-Osteoclastic Activity of Artemisia capillaris Thunb. Extract Depends
upon Attenuation of Osteoclast Differentiation and Bone Resorption-AssociatedAcidification Due to Chlorogenic Acid, Hyperoside, and Scoparone. Int J Mol Sci.
2017, 18(2) 322. PMID: 28165389
10) Lee DH, Nutrikinetics of Isoflavone Metabolites After Fermented Soybean Product(Cheonggukjang) Ingestion in Ovariectomized Mice. Mol Nutr Food Res. 2017, 61(12).
PMID: 2898120111) Funaki Y, Resolvin E1 Inhibits Osteoclastogenesis and Bone Resorption bySuppressing IL-17-induced RANKL Expression in Osteoblasts and RANKL-induced
Osteoclast Differentiation. Yonago Acta Med. 2018, 61(1):8-18. PMID: 29599617
12) Chu G, Punicalagin inhibits RANKL-induced osteoclastogenesis by suppressing NFκB and MAPK signaling pathways. Int J Clin Exp Med 2018;11(7):6571-6582.
13) Sapkota M, Thymol inhibits RANKL-induced osteoclastogenesis in RAW264.7 andBMM cells and LPS-induced bone loss in mice. Food Chem Toxicol, 2018, 120:418429. PMID: 30048646
14) Na S, Dose analysis of photobiomodulation therapy on osteoblast, osteoclast, andosteocyte. J Biomed Opt, 2018, 23(7):1-8. PMID: 30030913
15) Watahiki A, Deficiency of Lipin2 Results in Enhanced NF-κB Signaling andOsteoclast Formation in RAW-D Murine Macrophages. Int J Mol Sci, 2021,
22(6):2893. PMID: 33809261
16) Zang L, 10-Gingerol Suppresses Osteoclastogenesis in RAW264.7 Cells and Zebrafish
Osteoporotic Scales. Front Cell Dev Biol, 2021 9:588093. PMID: 33748100
17) Akashi Y, Cyclic Pressure-Induced Cytokines from Gingival Fibroblasts Stimulate
Osteoclast Activity: Clinical Implications for Alveolar Bone Loss in Denture Wearers.
J Prosthodont Res, 2022. PMID: 35185110
18) Mohamad Hazir NS, Changes in Metabolism and Mitochondrial Bioenergetics
during Polyethylene-Induced Osteoclastogenesis. Int J Mol Sci. 2022, 23(15): 8331.
PMID: 3595546419) Ding L, Ginsenoside compound-K attenuates OVX-induced osteoporosis via thesuppression of RANKL-induced osteoclastogenesis and oxidative stress. Nat Prod
Bioprospect, 2023, 13(1):49. PMID: 37940733
20) Urabe F., Metastatic prostate cancer-derived extracellular vesicles facilitate
osteoclastogenesis by transferring the CDCP1 protein. J Extracell Vesicles, 2023,
12(3):e12312. PMID: 36880252
21) Rabjohns EM., Aged G Protein-Coupled Receptor Kinase 3 (Grk3)-Deficient Mice
Exhibit Enhanced Osteoclastogenesis and Develop Bone Lesions Analogous toHuman Paget’s Disease of Bone. Cells, 2023, 12(7):981. PMID: 3704805422) Kim SK., Histone Deacetylase 6 Inhibitor CKD-WID Suppressed Monosodium UrateInduced Osteoclast Formation by Blocking Calcineurin-NFAT Pathway in RAW 264.7Cells. Pharmaceuticals (Basel), 2023, 16(3):446. PMID: 36986544
23) Feldman G., Geranylgeraniol (GGOH), incorporated into a bone cement pellet
promotes osteoclast function and healing in a model of medication-related
osteonecrosis of the jaw. J Oral Biol Craniofac Res, 2024, 14(2):126-132. PMID:38327595
24) Dong J., Mechanistic study on the alleviation of postmenopausal osteoporosis by
Lactobacillus acidophilus through butyrate-mediated inhibition of osteoclast activity.
Sci Rep, 2024, 14(1):7042. PMID: 38528074

Bone marrow-derived macrophages1) Nishida H, Blockade of CD26 signaling inhibits human osteoclast development. J
Bone Miner Res, 2014, 29(11):2439-55. PMID: 24821427
2) Kang JH, Osteoprotegerin expressed by osteoclasts: an autoregulator ofosteoclastogenesis. J Dent Res. 2014, 93(11):1116-23. PMID: 25256714
3) Cheng TL, Myeloid thrombomodulin lectin-like domain inhibits osteoclastogenesis
and inflammatory bone loss. Sci Rep. 2016, 17;6:28340. PMID: 27311356

4) Joung YH, Methylsulfonylmethane Inhibits RANKL-Induced Osteoclastogenesis inBMMs

by Suppressing NF-κB

andSTAT3 Activities.

PLoS One. 2016,22;11(7):e0159891. PMID: 27447722
5) Abdallah BM, The Coumarin Derivative 5'-Hydroxy Auraptene Suppresses
Osteoclast Differentiation via Inhibiting MAPK and c-Fos/NFATc1 Pathways.
Biomed Res Int. 2019, 9395146. PMID: 31976330
6) Kim HY, Auranofin Inhibits RANKL-Induced Osteoclastogenesis by Suppressing
Inhibitors of κB Kinase and Inflammasome-Mediated Interleukin-1β Secretion. Oxid
Med Cell Longev. 2019, 2019:3503912. PMID: 31275508
7) Cho E., PSTP-3,5-Me Inhibits Osteoclast Differentiation and Bone Resorption.
Molecules, 2019, 24(18):3346. PMID: 31540026
8) Chen Z, 2-NPPA Mitigates Osteoclastogenesis via Reducing TRAF6-Mediated c-fosExpression. Front Pharmacol, 2021, 11:599081. PMID: 33033302
9) Chen Z, N-[2-(4-benzoyl-1-piperazinyl)phenyl]-2-(4-chlorophenoxy) acetamide is anovel inhibitor of resorptive bone loss in mice. J Cell Mol Med, 2021, 25(3):1425-1438.
PMID: 33369010
10) Toung D., Development of a Cause-based Treatment for NBP-induced MRONJ. J
Oral Maxillofac Surg, 2021, 79(10), e51-e52.
11) AlamMI,NLRP3Inflammasome

NegativelyRegulates

RANKL-Induced

Osteoclastogenesis of Mouse Bone Marrow Macrophages but Positively Regulates Itin the Presence of Lipopolysaccharides. Int J Mol Sci, 2022, 23(11):6096. PMID:3568277712) Li J, Sensory nerves directly promote osteoclastogenesis by secreting peptidyl-prolyl
cis-trans isomerase D (Cyp40). Bone Res, 2023, 11(1):64. PMID: 38097598
13) Tokuda K., Rab32 and Rab38 maintain bone homeostasis by regulating intracellulartraffic in osteoclasts. Cell Struct Funct, 2023, 48(2):223-239. PMID: 37793839

14) Whitlock JM, An inducible explant model of osteoclast-osteoprogenitor coordinationin exacerbated osteoclastogenesis. iScience, 2023, 26(4):106470. PMID: 37091244
15) Nakaue E., Mechanisms of preferential bone formation in myeloma bone lesions byproteasome inhibitors. Int J Hematol, 2023, 118(1):88-98. PMID: 37039914
16) de Castro LF., RANKL inhibition reduces lesional cellularity and Gαs variant
expression and enables osteogenic maturation in fibrous dysplasia. Bone Res, 2024,12(1):10. PMID: 38378678

Peripheral blood mononuclear cells
1) Steller D, Establishment and validation of an in vitro co-culture model for oral celllines using human PBMC-derived osteoclasts, osteoblasts, fibroblasts andkeratinocytes. Sci Rep, 2020, 10(1):16861. PMID: 33033302
2) Whitlock JM, Cell surface-bound La protein regulates the cell fusion stage ofosteoclastogenesis. Nat Commun, 2023, 14(1):616. PMID: 35955464